ABSTRACT
Background Due to the substantial proportion of asymptomatic and mild courses many SARS-CoV-2 infections remain unreported. Therefore, assessment of seroprevalence may detect the real burden of disease. We aimed at determining and characterizing the rate of SARS-CoV-2 infections and the resulting immunity in a defined population.
Methods CoNAN is a population-based cohort study in the previously quarantined community Neustadt-am-Rennsteig, Germany six weeks after a SARS-CoV-2 outbreak with 49 cases identified by PCR screening of all 883 inhabitants. The primary objective of the study was to assess SARS-CoV-2 antibody seroconversion rate using six different IgG detecting immunoassays. Secondary objectives of the study were: i.) to determine the rate of seroconversion in children; ii.) to determine potential risk factors for symptomatic vs. asymptomatic Covid19 courses; iii.) to investigate the rate of virus persistence.
Findings We enrolled 626 participants (71% of the community population). All actual SARS-CoV-2 PCR tests were negative; while a total of 8·4% (52 of 620 tested) had antibodies against SARS-CoV-2 in at least two independent tests. Twenty of the antibody positive participants had previously a positive SARS-CoV-2 PCR. On the contrary, of those 38 participants with SARS-CoV-2 infection, only 20 (52·6%) were antibody positive.
Interpretation Several antibody tests conducted six weeks after an outbreak of SARS-CoV-2 did not detect all previously PCR-positive tested individuals. Cautious evaluation of antibody testing strategies to assess immunity against the infection is warranted.
Funding CoNAN was funded by the Thuringian Ministry for Economic Affairs, Science and Digital Society (TMWWDG).
Competing Interest Statement
SW received speakers fees from MSD and Infectopharm. SH received speakers fees from Pfizer, MSD and Astra Zeneca. TK speakers fees from Roche MP has participated in international advisory boards from Pfizer, Novartis, Basilea and Cubist and received speakers fees from the same companies. CB has participated in advisory boards from GSK and received speakers fees from Pfizer. All other authors do not report any conflict of interest
Clinical Trial
DRKS00022416 (submitted)
Funding Statement
CoNAN was funded by the Thuringian Ministry for Economic Affairs, Science and Digital Society (TMWWDG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the current version of the Declaration of Helsinki and has been approved by the institutional ethics committees of the Jena University Hospital and the respective data protection commissioner (approval number 2020-1776) and the ethics committee of the Thuringian chamber of physicians.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Study Group: Technische Universität Ilmenau, Ilmenau, Germany: Thomas Hotz
Local Cooperation partners: Petra Enders, Renate Koch, Steffen Mai, Matthias Ullrich
Thuringian state office for consumer protection, Bad Langensalza, Germany: Dagmar Rimek.
Institute of Clinical Chemistry and Laboratory Diagnostics and Integrated Biobank Jena (IBBJ), Jena, Germany: Cora Richert, Cornelius Eibner, Bettina Meinung, Kay Stötzer, Julia Köhler.
Children’s Hospital, JUH, Jena, Germany: Hans Cipowicz, Christine Pinkwart
Department of Anesthesiology and Intensive Care Medicine, JUH, Jena, Germany: Michael Bauer, Petra Dickmann, Annika Licht, Juliane Scholz, Wibke Wetzker.
Institute for Infectious Disease and Infection Control, JUH, Jena, Germany: Anita Hartung, Daniel Weiss, Lara Thieme, Gabi Hanf, Clara Schnizer, Jasmin Müller, Jennifer Kosenkow, Franziska Röstel
Institute of Immunology, JUH, Jena, Germany: Nico Andreas, Raphaela Marquardt
Institute of Medical Microbiology, JUH, Jena, Germany: Stefanie Deinhardt-Emmer, Sebastian Kuhn
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request after publication of the manuscript.
ABBREVIATIONS
- CI
- confidence interval
- GEE
- generalized estimation equations
- MERS-CoV
- Middle East respiratory syndrome-related coronavirus
- OR
- odds ratio
- SARS-CoV
- severe acute respiratory syndrome-related coronavirus
